Psychopharmacological interventions in autism spectrum disorder

Harvard Review of Psychiatry

Volumn 22, Issue 2, 2014, Pages 76-92

  Politte, Laura C ^a   Henry, Charles A ^a   McDougle, Christopher J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticonvulsants; Antidepressants; Atypical antipsychotics; Autism; Autism spectrum disorders; Mood stabilizers; Oxytocin; Pervasive developmental disorders; Psychopharmacology; Stimulants

Indexed keywords

ACETYLCYSTEINE; ANTICONVULSIVE AGENT; ARBACLOFEN; ARIPIPRAZOLE; ASENAPINE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CYCLOSERINE; DESIPRAMINE; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GLUTAMIC ACID; GUANFACINE; LAMOTRIGINE; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; OXCARBAZEPINE; OXYTOCIN; RISPERIDONE; SEROTONIN AGONIST; TOPIRAMATE; UNINDEXED DRUG; ZIPRASIDONE; PSYCHOTROPIC AGENT;

ADVERSE OUTCOME; AGGRESSION; ANXIETY; ATTENTION DEFICIT DISORDER; AUTISM; COMPULSION; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; HYPERACTIVITY; IMPULSIVENESS; IRRITABILITY; MENTAL INSTABILITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CHILD DEVELOPMENT DISORDERS, PERVASIVE; PATHOPHYSIOLOGY;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; PSYCHOTROPIC DRUGS;

EID: 84902159757     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000030     Document Type: Review

References (190)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Press, 2000.
2. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Prinicipal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61:1-19.
3. Blumberg SJ, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. Natl Health Stat Report 2013;(65):1-28.
4. Cadman T, Eklund H, Howley D, et al. Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 2012;51:879-88.
5. Cidav Z, Marcus SC, Mandell DS. Implications of childhood autism for parental employment and earnings. Pediatrics 2012;129:617-23.
6. Peacock G, Amendah D, Ouyang L, Grosse SD. Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions. J Dev Behav Pediatr 2012;33:2-8.
7. Cimera RE, Cowan RJ. The costs of services and employment outcomes achieved by adults with autism in the US. Autism 2009;13:285-302.
8. Shattuck PT, Roux AM, Hudson LE, Taylor JL, Maenner MJ, Trani JF. Services for adults with an autism spectrum disorder. Can J Psychiatry 2012;57:284-91.
9. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;10:CD009260.
10. Joshi G, Petty C, Wozniak J, et al. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population. J Autism Dev Disord 2010;40:1361-70.
11. Coury DL, Anagnostou E, Manning-Courtney P, et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 2012;130 suppl 2:S69-76.
12. Mazefsky CA, Conner CM, Oswald DP. Association between depression and anxiety in high-functioning children with autism spectrum disorders and maternal mood symptoms. Autism Res 2010;3:120-7.
13. Mazefsky CA, Folstein SE, Lainhart JE. Overrepresentation of mood and anxiety disorders in adults with autism and their first-degree relatives: what does it mean? Autism Res 2008;1:193-7.
14. Strang JF, Kenworthy L, Daniolos P, et al. Depression and anxiety symptoms in children and adolescents with autism spectrum disorders without intellectual disability. Res Autism Spectr Disord 2012;6:406-12.
15. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008;23:482-5. (Pubitemid 351566859)
16. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21:700-9.
17. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32:585-9. (Pubitemid 44210097)
18. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An openlabel study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006;36:741-52. (Pubitemid 44284978)
19. Guenole F, Godbout R, Nicolas A, Franco P, Claustrat B, Baleyte JM. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev 2011;15:379-87.
20. Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012;42:1729-37; author reply 1738.
21. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44:57-64. (Pubitemid 350231110)
22. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5:145-50.
23. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011;41:175-84.
24. Bethea TC, Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry 2007;61:521-37. (Pubitemid 46185342)
25. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008;47:921-9.
26. Brasic JR, Barnett JY, Kaplan D, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994;44:1309-12. (Pubitemid 24232235)
27. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997;7:109-21. (Pubitemid 27421349)
28. McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 1992;31:746-50.
29. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry 1997;36:1165-6.
30. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996;35:537-44. (Pubitemid 126418618)
31. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992;149:363-6.
32. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-7. (Pubitemid 23169937)
33. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 1991;30:508-9.
34. Alcami Pertejo M, Peral Guerra M, Gilaberte I. [Open study of fluoxetine in children with autism]. Actas Espanolas de Psiquiatria 2000;28:353-6.
35. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 2001;4:119-25. (Pubitemid 32587378)
36. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002;44:652-9. Comment: Bates G, Willson SW. Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania. Dev Med Child Neurol 2003;45:359; author reply 360.
37. DeLong GR, Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-62. Comment: Bax M. A treatment that works. Dev Med Child Neurol 1998;40:507.
38. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-6. (Pubitemid 26277885)
39. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-6. (Pubitemid 28045636)
40. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003;24:104-8. (Pubitemid 36546777)
41. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005;44:343-8. (Pubitemid 40393272)
42. Desousa A. An open-label trial of risperidone and fluoxetine in children with autistic disorder. Indian J Psychol Med 2010;32:17-21.
43. Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol 2006;16:187-95.
44. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9-15. (Pubitemid 27252846)
45. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8. (Pubitemid 26384669)
46. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry 2012;169:292-9.
47. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000;30:427-35.
48. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-9. (Pubitemid 40271160)
49. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66:583-90.
50. Autism Speaks. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA): first industrysponsored trial for the Autism Clinical Trials Network (ACTN) [Press release]. 18 Feb 2009. http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces- resultsreported-study-fluoxetine-autism-sofia
51. McDougle CJ, Posey D. Genetics of childhood disorders: XLIV. Autism, part 3: psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry 2002;41:1380-3. (Pubitemid 38338031)
52. Brahm NC, Fast GA, Brown RC. Buspirone for autistic disorder in a woman with an intellectual disability. Ann Pharmacother 2008;42:131-7.
53. Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an openlabel study. J Clin Psychiatry 1998;59:56-9. (Pubitemid 28141236)
54. McCormick LH. Treatment with buspirone in a patient with autism. Arch Fam Med 1997;6:368-70. (Pubitemid 127439280)
55. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989;9:122-5. (Pubitemid 19098159)
56. Albertini G, Polito E, Sara M, Di Gennaro G, Onorati P. Compulsive masturbation in infantile autism treated by mirtazapine. Pediatr Neurol 2006;34:417-8.
57. Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. J Child Adolesc Psychopharmacol 2009;19:203-6.
58. Coskun M, Mukaddes NM. Mirtazapine treatment in a subject with autistic disorder and fetishism. J Child Adolesc Psychopharmacol 2008;18:206-9. (Pubitemid 351591436)
59. Nguyen M, Murphy T. Mirtazapine for excessive masturbation in an adolescent with autism. J Am Acad Child Adolesc Psychiatry 2001;40:868-9. (Pubitemid 32667065)
60. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001;11:267-77. (Pubitemid 32937638)
61. Leyfer OT, Folstein SE, Bacalman S, et al.Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 2006;36:849-61. (Pubitemid 44440104)
62. Aman MG. Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil 1996;4:347-66. (Pubitemid 126158910)
63. Campbell M, Small AM, Hollander CS, et al. A controlled crossover study of triiodothyronine in autistic children. J Autism Child Schizophr 1978;8:371-81. (Pubitemid 10133273)
64. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:49-56. (Pubitemid 38525953)
65. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 1988;27:248-51. (Pubitemid 18089217)
66. Geller B, Guttmacher LB, Bleeg M. Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. Am J Psychiatry 1981;138:388-9.
67. Hoshino Y, Kumashiro H, Kaneko M, Takahashi Y. The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels. Folia Psychiatr Neurol Jpn 1977;31:605-14. (Pubitemid 8306575)
68. Strayhorn JM Jr, Rapp N, Donina W, Strain PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry 1988;27:244-7. (Pubitemid 18089216)
69. Vitriol C, Farber B. Stimulant medication in certain childhood disorders. Am J Psychiatry 1981;138:1517-8. (Pubitemid 11030335)
70. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-55.
71. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25:283-94.
72. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-74.
73. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001;40:180-7. (Pubitemid 32111021)
74. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol 2009;19:329-39.
75. King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res 2011;1380:34-41.
76. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attentiondeficit/hyperactivity disorder. Pediatrics 2008;121:e73-84.
77. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, doubleblind, placebo-controlled trial. CNS Drugs 2010;24:755-68.
78. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65.
79. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000;39:15-25. (Pubitemid 30044196)
80. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:171-9.
81. Kollins SH, Jain R, Brams M, et al. Clonidine extendedrelease tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011;127: e1406-13.
82. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008;30:454-60.
83. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
84. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12:322-7.
85. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-41. (Pubitemid 38988789)
86. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:589-98. (Pubitemid 44737213)
87. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008;29:303-8.
88. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:325-30. (Pubitemid 40734112)
89. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attentiondeficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:599-610. (Pubitemid 44739916)
90. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006;16:611-9. (Pubitemid 44737214)
91. Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr 2011;100:1258-61.
92. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord 2011;15:684-9.
93. Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/ hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012;51:733-41.
94. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebocontrolled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006;45:1196-205. (Pubitemid 44465640)
95. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40:658-65. (Pubitemid 32473379)
96. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21. (Pubitemid 34815353)
97. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-41.
98. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-41.
99. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002;41:140-7. (Pubitemid 38338162)
100. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21:450-5. (Pubitemid 44069792)
101. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137-44. (Pubitemid 41508125)
102. Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009;48:1143-54.
103. Aman MG, Arnold LE, McDougle CJ, et al. Acute and longterm safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005;15:869-84. (Pubitemid 43042978)
104. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007;37:367-73.
105. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004;161:1125-7. (Pubitemid 38736004)
106. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50. (Pubitemid 46185331)
107. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-9.
108. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-40.
109. Aman MG, Kasper W, Manos G, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 2010; 20:415-22.
110. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 2011;72:1270-6.
111. Ho JG, Caldwell RL, McDougle CJ, et al. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2012;22:277-83.
112. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-94. (Pubitemid 32667070)
113. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44. (Pubitemid 29047329)
114. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract 2008;17:415-8.
115. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-60.
116. Hollander E, Wasserman S, Swanson EN, et al. A doubleblind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-8. (Pubitemid 44737209)
117. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004;14:287-94. (Pubitemid 38988794)
118. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9:99-107. (Pubitemid 29379846)
119. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 2011; 34:216-9.
120. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004;65:1531-6.
121. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005;35: 387-91. (Pubitemid 41125976)
122. Duggal HS. Ziprasidone for maladaptive behavior and attention-deficit/ hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol 2007;17:261-3. (Pubitemid 46828924)
123. Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 2003;37:775-6. (Pubitemid 38072527)
124. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007;17:779-90. (Pubitemid 351158593)
125. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-7. (Pubitemid 38338071)
126. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004;65:110-3.
127. McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008;69 suppl 4:15-20.
128. Roser P, Haussleiter IS, Juckel G, Brune M. Paliperidone in an adult patient with Asperger syndrome: case report. Pharmacopsychiatry 2009;42:78-9.
129. Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol 2010;20:75-8.
130. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl) 2012;223:237-45.
131. Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001;62:479-80. (Pubitemid 32717889)
132. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001;26:340-1. (Pubitemid 32912430)
133. Lambrey S, Falissard B, Martin-Barrero M, et al. Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol 2010;20:79-80.
134. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996;153:738. (Pubitemid 26133642)
135. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26:733-59.
136. Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol 2006;26:444-6. (Pubitemid 44187659)
137. Childs JA, Blair JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs 1997;29:244-8.
138. Plioplys AV. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 1994;148:220-2. (Pubitemid 24071399)
139. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62:530-4. (Pubitemid 32703092)
140. Hellings JA, Weckbaugh M, Nickel EJ, et al. A doubleblind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-92. (Pubitemid 41434372)
141. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35:990-8.
142. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9:209-13. (Pubitemid 43255834)
143. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;31:175-81. (Pubitemid 37490163)
144. Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a doubleblind placebo-controlled study. Int Clin Psychopharmacol 2006;21:363-7. (Pubitemid 44498278)
145. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002;23:225-30. (Pubitemid 34947180)
146. Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am J Psychiatry 2007; 164:832-3. (Pubitemid 46808549)
147. Douglas JF, Sanders KB, Benneyworth MH, et al. Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder. J Autism Dev Disord 2013;43:1243-7.
148. Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:426-32. (Pubitemid 39473128)
149. Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 2006;28:668.
150. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-32. (Pubitemid 40312035)
151. Lukas M, Neumann ID. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res 2013;251:85-94.
152. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43:270-7. (Pubitemid 28085673)
153. Sauer C, Montag C, Worner C, Kirsch P, Reuter M. Effects of a common variant in the CD38 gene on social processing in an oxytocin challenge study: possible links to autism. Neuropsychopharmacology 2012;37:1474-82.
154. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mind-reading" in humans. Biol Psychiatry 2007;61:731-3.
155. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 2012;3:16.
156. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67: 692-4.
157. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007;61:498-503. (Pubitemid 46185336)
158. Kosaka H, Munesue T, Ishitobi M, et al. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 2012;12:110.
159. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003; 28:193-8.
160. ClinicalTrials.gov. http://www.clinicaltrials.gov
161. Ring RH, Schechter LE, Leonard SK, et al.Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010;58:69-77.
162. Carlson GC. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol Biochem Behav 2012;100:850-4.
163. Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One 2012;7:e36981.
164. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-9. (Pubitemid 46951501)
165. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 2007;191:141-7. (Pubitemid 46294942)
166. Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry 2006;67:1000. (Pubitemid 44049107)
167. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an openlabel trial. Biol Psychiatry 2005;58:424-8. (Pubitemid 41219711)
168. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res 2011;1380:264-70.
169. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17:761-7. (Pubitemid 351158597)
170. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61: 822-5. (Pubitemid 46330247)
171. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161:171-4. (Pubitemid 38419327)
172. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430-2. (Pubitemid 40215774)
173. Veenstra-VanderWeele J. Increase in valproic acid levels during riluzole treatment in an adolescent with autism. J Child Adolesc Psychopharmacol 2010;20:163-5.
174. Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. J Child Adolesc Psychopharmacol 2011; 21:375-9.
175. Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2010;20: 309-15.
176. Won H, Lee HR, Gee HY, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012;486:261-5.
177. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161:2115-7. (Pubitemid 39441414)
178. Goff DC, Herz L, Posever T, et al. A six-month, placebocontrolled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005;179:144-50. (Pubitemid 40576701)
179. Moskal JR, Burgdorf J, Kroes RA, Brudzynski SM, Panksepp J. A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism. Neurosci Biobehav Rev 2011;35:1982-8.
180. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64:361-8.
181. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64:468-75.
182. Berk M, Dean O, Cotton SM, et al. The efficacy of Nacetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011; 135:389-94.
183. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652-7. (Pubitemid 47314380)
184. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184:254-6. (Pubitemid 43084809)
185. Magalhaes PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011;33:374-8.
186. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012;71:956-61.
187. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4:152ra27.
188. Seaside Therapeutics. Seaside Therapeutics reports positive data from phase 2 study of STX209 in autismspectrum disorders [Press release]. 9 Sep 2010. http://www.businesswire.com/news/home/20100909005766/en#UstybvQW0vw
189. Seaside Therapeutics. Seaside Therapeutics to announce results from a phase 2b clinical trial of arbaclofen in autism spectrum disorder at the International Meeting for Autism Research (IMFAR) 2013 conference [Press release]. 1 May 2013. http://www.businesswire.com/news/home/20130501006067/en/ Seaside-Therapeutics-Announce-Results-Phase-2b-Clinical#.UstzHfQW0vw
190. Scott MM, Deneris ES. Making and breaking serotonin neurons and autism. Int J Dev Neurosci 2005;23:277-85. (Pubitemid 40313559)